Sydney
Meridan ReportSydney: Australian finance, Asia-Pacific tech bridge

Advertisement · Why this ad?

Business

A kill switch for epilepsy? China cuts seizures by 92.6% in first human chemogenetic trial

Katherine Langford
Editor-in-Chief · Friday, November 6, 2026 at 1:00 PM · 1 min read
A kill switch for epilepsy? China cuts seizures by 92.6% in first human chemogenetic trial — Sydney Business news

For people living with refractory epilepsy, the brain is like a city that can suffer a blackout any time lightning strikes. Without warning, an abnormal neural discharge can sweep through the intracranial circuits, leaving behind convulsions, loss of consciousness and years of lingering panic. Around one-third of epilepsy patients worldwide are completely unresponsive to existing medications, while traditional craniotomy resection surgery often carries the risk of irreversible neurological...

Up nextMore funding could be sought if HK$10b university town loan scheme falls shortBusiness · 1 min read
You're offline — showing the last loaded page